Comparable stake leader
7. Cooperative Ua Lsp
SEC ownership of Agomab Therapeutics NV
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0002020932.
Disclosed value leader
EQT Fund Management S.a r.l.
Comparable rows
37/37
Latest evidence
30 Jun 2026
- Public ticker
- AGMB on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
7. Cooperative Ua Lsp
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
37 of 37
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
7. Cooperative Ua Lsp
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0002020932
- Issuer location
- Antwerpen
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Agomab Therapeutics NV (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
7. Cooperative Ua Lsp
Disclosed value leader
EQT Fund Management S.a r.l.
Comparable rows
37/37
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 11%
13D/G row: 7. Cooperative Ua Lsp
Showing 1-8 of 37 holder rows.
Quick read
7. Cooperative Ua Lsp leads the comparable SEC ownership view at 11%.
37 of 37 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens 7. Cooperative Ua Lsp's linked filing trail.
Comparable ownership
Top 5
7. Cooperative Ua Lsp
11%
FMR LLC
10%
Pontifax Management 4 G.P. (2015)...
6.8%
Sanofi
5.7%
Redmile Group, LLC
5.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 37 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| 7. Cooperative Ua Lsp |
13D/G
LSP 7 Cooperatieve U.A.
|
11%
|
—
5,141,992 shares
|
$0 | 09 Feb 2026 |
| FMR LLC |
13F
13D/G
Company
|
10%
from 13D/G
|
$18,933,627
1,458,677 shares
|
— | 30 Jun 2026 |
| Pontifax Management 4 G.P. (2015) Ltd. |
13D/G
Pontifax VI G.P. L.P.
|
6.8%
|
—
3,305,846 shares
|
$0 | 31 Mar 2026 |
| Sanofi |
13F
13D/G
Company
|
5.7%
from 13D/G
|
$36,124,586
2,783,096 shares
|
— | 30 Jun 2026 |
| Redmile Group, LLC |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$35,486,359
2,733,926 shares
|
— | 30 Jun 2026 |
| Cormorant Asset Management, LP |
13F
13D/G
Company
|
5%
from 13D/G
|
$32,000,217
2,465,348 shares
|
— | 30 Jun 2026 |
| Tim Jasper Knotnerus |
3/4/5
Chief Executive Officer, Director
|
0.09%
|
—
45,217 shares
|
— | 18 Mar 2026 |
| EQT Fund Management S.a r.l. |
13F
Company
|
10%
|
$66,743,056
5,141,992 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 14 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to Agomab Therapeutics NV. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Philippe Constantin Wiesel
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Philippe Constantin Wiesel | Chief Medical Officer | Mixed | 18 Mar 2026 | |||
| Ellen Lefever | General Counsel | Mixed | 18 Mar 2026 | |||
| Andrea Saez Borderias | Chief Development Officer | Mixed | 18 Mar 2026 | |||
| Isabel Verduyn van Weegen | Director | Mixed | 18 Mar 2026 | |||
| Paul Henryk van der Horst | Chief Business Officer | Mixed | 18 Mar 2026 | |||
| Angelika Martha Jahreis | Director | Mixed | 18 Mar 2026 | |||
| Pierre Thadee Victor Kemula | Chief Financial Officer | Mixed | 18 Mar 2026 | |||
| Ohad Hammer | Director | Mixed | 18 Mar 2026 | |||
| Colin Michael Bond | Director | Mixed | 18 Mar 2026 | |||
| Tim Jasper Knotnerus | Chief Executive Officer, Director | Mixed | 18 Mar 2026 | |||
| David R. Epstein | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for Agomab Therapeutics NV
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Tim Jasper Knotnerus | AGMB | Common shares | 0 | 34,394 | 18 Mar 2026 | By TJK Life Sciences B.V. | ||||
| Tim Jasper Knotnerus | AGMB | Common shares | 0 | 10,823 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.